Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

FOLFIRINOX

Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours

Trial Locations (1)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER